Furthermore, many new preclinical studies have shown that a DNA vaccine encoding the prostate-associated antigen prostatic acid phosphatase (PAP) can elicit PAP-specific CD8+ T-cell immune responses, as seen in a phase I/II study employing a DNA vaccine that encoded human PAP conducted in 22 prostate cancer patients [204]. Here, ACP3 is linked to prostate carcinoma.